Validation of a Predictive Nomogram of Response or Resistance to Targeted Therapies in Metastatic Clear Cell Renal Cell Carcinoma

Rennes University Hospital45 enrolled

Overview

The purpose of this study is to validate of a predictive nomogram of response or resistance to targeted therapies in metastatic clear cell renal cell carcinoma

Study Type

OBSERVATIONAL

Enrollment

Conditions

Metastatic Clear Cell Renal Cell Carcinoma

Interventions

SunitinibDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients with metastatic ccRCC * Underwent nephrectomy at the University Hospital of Rennes * treated by sunitinib first line treatment Exclusion Criteria: * translocation renal cell carcinoma * other targeted therapies before the sunitinib

Locations (1)

CHU de Rennes

Rennes, France

Outcomes

Primary Outcomes

Primary refractory patients (Progression Free Survival (PFS)

Time frame: at 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.